Dimerix says observational analysis could back speedier path to market for rare kidney disease drug

Dimerix said an observational study of patients with a rare kidney disease has yielded data that could support its hopes of pursuing accelerated approval in the US for its late-stage asset. The Australian biotech’s CCR2 ...